Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Studies Reporting Adverse Effects Associated With DMARDs
Thirteen randomized controlled trials describing 14 DMARD interventions included a placebo comparison and reported adverse effects; 914 unique patients were included.
One hundred fifty-one publications reported adverse effects in patients with JIA and treated with DMARDs; 4,344 patients were included. Patient populations in the reports may overlap with randomized controlled trials and with each other.
Two studies reported cases of malignancies in children undergoing DMARD treatment for JIA. The patient populations of these studies were not identified.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | adverse effects
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.